Anemia: progress in molecular mechanisms and therapies
暂无分享,去创建一个
[1] Isaure Chauvot de Beauchêne,et al. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia , 2014, Nature.
[2] E. Lander,et al. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13 , 2011, Proceedings of the National Academy of Sciences.
[3] T. Graeber,et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.
[4] D. Weatherall. The inherited diseases of hemoglobin are an emerging global health burden. , 2010, Blood.
[5] S. Goh,et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin , 2007, Nature Medicine.
[6] V. Sankaran. BCL 11 A by the Developmental Stage-Specific Repressor Human Fetal Hemoglobin Expression Is Regulated , 2008 .
[7] W. Jelkmann. Pathophysiology and Pharmacology of Erythropoietin , 1992 .
[8] Hans Martin,et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.
[9] G. Kato,et al. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. , 2014, Hematology/oncology clinics of North America.
[10] E. Hod,et al. CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso‐occlusion during hemolytic transfusion reactions , 2011, The Journal of clinical investigation.
[11] J. D. Engel,et al. Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes , 2011, Proceedings of the National Academy of Sciences.
[12] S. Rivella,et al. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. , 2013, The Journal of clinical investigation.
[13] Matthew C. Canver,et al. An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level , 2013, Science.
[14] M. Cappellini,et al. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. , 2012, Blood.
[15] V. Jha,et al. Chronic kidney disease: global dimension and perspectives , 2013, The Lancet.
[16] Richard T. Lee,et al. Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors , 2014, Science.
[17] S. Brown,et al. Balancing act. , 1996, The Canadian nurse.
[18] K. Finberg. Striking the target in iron overload disorders. , 2013, The Journal of clinical investigation.
[19] F. Locatelli,et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. , 2013, Blood.
[20] D. Neuberg,et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. , 2013, Blood.
[21] S. Chou. Transfusion therapy for sickle cell disease: a balancing act. , 2013, Hematology. American Society of Hematology. Education Program.
[22] A. D. de Brevern,et al. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. , 2010, American journal of human genetics.
[23] N. Mohandas,et al. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. , 1984, The New England journal of medicine.
[24] C. Witmer. Hematologic manifestations of systemic disease (including iron deficiency, anemia of inflammation and DIC). , 2013, Pediatric clinics of North America.
[25] G. Jennings. Death by a Thousand Cuts [Book Review] , 2009 .
[26] A. Fricot,et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia , 2014, Nature Medicine.
[27] Yijun Yang,et al. Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women , 2013, Journal of clinical pharmacology.
[28] Charles B. Hall,et al. Transferrin therapy ameliorates disease in β-thalassemic mice , 2010, Nature Medicine.
[29] H. Nakauchi,et al. Clonal Analysis Unveils Self-Renewing Lineage-Restricted Progenitors Generated Directly from Hematopoietic Stem Cells , 2013, Cell.
[30] C. Bokemeyer,et al. Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment , 2005, Oncology.
[31] I. Macdougall,et al. Peginesatide in patients with anemia undergoing hemodialysis. , 2013, The New England journal of medicine.
[32] I. Macdougall. New anemia therapies: translating novel strategies from bench to bedside. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[33] I. Macdougall,et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. , 2013, The New England journal of medicine.
[34] S. Orkin,et al. The switch from fetal to adult hemoglobin. , 2013, Cold Spring Harbor perspectives in medicine.
[35] Michel Sadelain,et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin , 2000, Nature.
[36] W. Jelkmann. Physiology and Pharmacology of Erythropoietin , 2013, Transfusion Medicine and Hemotherapy.
[37] E. Lander,et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. , 2012, The Journal of clinical investigation.
[38] S. Rivella,et al. Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. , 2014, Hematology/oncology clinics of North America.
[39] P. Newburger,et al. Novel deletion of RPL15 identified by array-comparative genomic hybridization in Diamond–Blackfan anemia , 2013, Human Genetics.
[40] H. Lodish,et al. Transcriptional divergence and conservation of human and mouse erythropoiesis , 2014, Proceedings of the National Academy of Sciences.
[41] Richard T. Lee,et al. Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle , 2014, Science.
[42] R. Nagel,et al. Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy , 2001, Science.
[43] N. Raje,et al. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. , 2010, Current opinion in molecular therapeutics.
[44] S. Rivella,et al. IDENTIFICATION OF ERYTHROFERRONE AS AN ERYTHROID REGULATOR OF IRON METABOLISM , 2014, Nature Genetics.
[45] Kiran Musunuru,et al. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. , 2014, The Journal of clinical investigation.
[46] Huimin Zhao,et al. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. , 2014, Biotechnology and bioengineering.
[47] K. Markianos,et al. Rare complete loss of function provides insight into a pleiotropic genome-wide association study locus. , 2013, Blood.
[48] C. Burt,et al. The Human Perspective , 2015, Perspectives in biology and medicine.
[49] V. Sankaran,et al. Thalassemia: an overview of 50 years of clinical research. , 2010, Hematology/oncology clinics of North America.
[50] P. Frenette,et al. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. , 2013, Hematology. American Society of Hematology. Education Program.
[51] J. Małyszko. New renal anemia drugs: is there really anything new on the horizon? , 2014, Expert opinion on emerging drugs.
[52] D. Abraham,et al. 5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells †,‡ , 2005, British journal of haematology.
[53] Christopher J. Schofield,et al. Oxygen sensing by HIF hydroxylases , 2004, Nature Reviews Molecular Cell Biology.
[54] F. Grosveld,et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes Hereditary Persistence of Fetal Hemoglobin , 2010, Nature Genetics.
[55] S. Rivella,et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. , 2010, The Journal of clinical investigation.
[56] Danielle A. Simmons,et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice , 2014, Nature Medicine.
[57] T. Ganz,et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. , 2012, Blood.
[58] T. Ganz. Systemic iron homeostasis. , 2013, Physiological reviews.
[59] Jérôme Larghero,et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.
[60] P. Frenette,et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. , 2010, Blood.
[61] M. van der Burg,et al. Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.
[62] Jacob C. Ulirsch,et al. Altered Chromatin Occupancy of Master Regulators Underlies Evolutionary Divergence in the Transcriptional Landscape of Erythroid Differentiation , 2014, PLoS genetics.
[63] R. Strieter,et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. , 2009, Blood.
[64] S. Rivella,et al. Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response. , 2013, The Journal of clinical investigation.
[65] S. Orkin,et al. Genome-wide association studies of hematologic phenotypes: a window into human hematopoiesis. , 2013, Current opinion in genetics & development.
[66] S. Pai,et al. Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[67] V. Sankaran,et al. Targeted therapeutic strategies for fetal hemoglobin induction. , 2011, Hematology. American Society of Hematology. Education Program.
[68] Joel N Hirschhorn,et al. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation , 2010, Nature Genetics.
[69] H. Hasle,et al. Nathan and Oski’s Hematology of Infancy and Childhood , 2010 .
[70] S. Rivella,et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. , 2008, Blood.
[71] F. Bushman,et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.
[72] J. Segovia,et al. Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[73] A. Grinberg,et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis , 2014, Nature Medicine.
[74] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[75] I. Lamrissi‐Garcia,et al. Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. , 2008, American journal of human genetics.
[76] W. V. van IJcken,et al. HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. , 2014, The Journal of clinical investigation.
[77] T. Golub,et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease , 2010, Proceedings of the National Academy of Sciences.
[78] Philip D. Gregory,et al. Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping , 2014, Cell.
[79] Osamu Tanabe,et al. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction , 2013, Nature Medicine.
[80] S. Milstein,et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. , 2013, Blood.
[81] J. Price,et al. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. , 1998, Blood.
[82] D. Gutsaeva,et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. , 2011, Blood.
[83] Elizabeta Nemeth,et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.
[84] S. Orkin,et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. , 2011, Blood.
[85] Richard T. Lee,et al. Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy , 2013, Cell.
[86] O. Platt,et al. Hydroxyurea for the treatment of sickle cell anemia. , 2008, The New England journal of medicine.
[87] L. Naldini. Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.
[88] M. Gladwin,et al. Erythroid DAMPs drive inflammation in SCD. , 2014, Blood.
[89] Y. Kan,et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac , 2014, Genome research.
[90] Chris Fisher,et al. A functional element necessary for fetal hemoglobin silencing. , 2011, The New England journal of medicine.
[91] Tamir Kanias,et al. Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. , 2012, The Journal of clinical investigation.
[92] D. Lipschitz,et al. Interferon‐γ exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development , 1995 .
[93] M. Gladwin,et al. Sickle-cell disease , 2010, The Lancet.
[94] L. Bogun. ANEMIA OF CHRONIC DISEASE , 2015 .
[95] J. Palis. Primitive and definitive erythropoiesis in mammals , 2013, Front. Physiol..
[96] L. Usvyat,et al. Anaphylaxis and hypotension after administration of peginesatide. , 2014, The New England journal of medicine.
[97] Elisa Laurenti,et al. Hematopoiesis: a human perspective. , 2012, Cell stem cell.
[98] Ronald W. Barrett,et al. Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin , 1996, Science.
[99] Vanessa Taupin,et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.
[100] P. Frenette,et al. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. , 2007, Blood.
[101] S. Karlsson,et al. Gene therapy of Diamond Blackfan anemia CD34(+) cells leads to improved erythroid development and engraftment following transplantation. , 2008, Experimental hematology.
[102] S. Perrotta,et al. Hereditary spherocytosis , 2008, The Lancet.
[103] M. Sadelain,et al. Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. , 2000, Blood.
[104] R. Bejar,et al. Recent developments in myelodysplastic syndromes. , 2014, Blood.
[105] S. Agarwal,et al. Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia , 2011, Nature Medicine.
[106] Allon M. Klein,et al. Clonal dynamics of native haematopoiesis , 2014, Nature.
[107] R. Paulson. Targeting a new regulator of erythropoiesis to alleviate anemia , 2014, Nature Medicine.
[108] Seth R Flaxman,et al. A systematic analysis of global anemia burden from 1990 to 2010. , 2014, Blood.
[109] Jie Li,et al. Global transcriptome analyses of human and murine terminal erythroid differentiation. , 2014, Blood.
[110] S. Orkin,et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A , 2013, Proceedings of the National Academy of Sciences.
[111] Wouter W van Solinge,et al. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. , 2005, Blood.
[112] M. Weiss,et al. Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia. , 2012, Blood.
[113] Cong Peng,et al. Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing , 2011, Science.
[114] I. Macaulay,et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy , 2013, Nature.
[115] Elizabeta Nemeth,et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. , 2011, The Journal of clinical investigation.
[116] J. D. Engel,et al. Fetal Globin Gene Repressors as Drug Targets for Molecular Therapies To Treat the β-Globinopathies , 2014, Molecular and Cellular Biology.
[117] Stuart H. Orkin,et al. Developmental and species-divergent globin switching are driven by BCL11A , 2009, Nature.
[118] P. Dubus,et al. Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors. , 2012, American journal of human genetics.
[119] Philippe Joly,et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach , 2011, Nature Genetics.
[120] J. Spivak. The anaemia of cancer: death by a thousand cuts , 2005, Nature Reviews Cancer.
[121] Richard van Wijk,et al. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis , 2005 .
[122] P. Gregory,et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.
[123] S. Orkin,et al. Nathan and Oski's hematology of infancy and childhood , 2013 .
[124] E. Lander,et al. Altered translation of GATA1 in Diamond-Blackfan anemia , 2014, Nature Medicine.